Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eluxadoline in IBS-D with or without BAM
NCT03441581Phase 4Completed
- Sponsor
- Allergan
- Start
- Feb 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of eluxadoline in Irritable bowel syndrome with diarrhea (IBS-D) (2 arms), sponsored by Allergan. Primary endpoints: Change From Baseline in Average Bristol Stool Form Scale (BSFS) Score at 4 weeks, Percentage of Participants With Treatment-Emergent Adverse Events at 4 weeks and 3 more. Started Feb 2018; status: completed.
02
Drugs
eluxadoline
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT03441581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03441581.